Suppr超能文献

在伊朗巴姆进行的单剂量灭活硕大利什曼原虫加卡介苗预防人源性皮肤利什曼病的随机疫苗试验。

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

作者信息

Sharifi I, FeKri A R, Aflatonian M R, Khamesipour A, Nadim A, Mousavi M R, Momeni A Z, Dowlati Y, Godal T, Zicker F, Smith P G, Modabber F

机构信息

Kerman University of Medical Sciences, Medical School, Iran.

出版信息

Lancet. 1998 May 23;351(9115):1540-3. doi: 10.1016/S0140-6736(98)09552-X.

Abstract

BACKGROUND

A vaccine consisting of a single dose of whole-cell autoclave-killed Leishmania major (ALM) mixed with BCG was assessed in comparison with BCG alone against anthroponotic (human to human transmission) cutaneous leishmaniasis in a randomised double-blind trial in Bam, Iran.

METHODS

3637 schoolchildren, aged 6-15 years, with no history of cutaneous leishmaniasis and no response to a leishmanin skin test, were randomly assigned to receive 1 mg ALM mixed with BCG (n = 1839), or BCG alone (n = 1798). Safety of the vaccine and the incidence of confirmed cases of cutaneous leishmaniasis were followed up for 2 years.

FINDINGS

Side-effects were those usually associated with BCG vaccination, but tended to persist longer in the ALM + BCG group. After exclusion of four cases occurring within 80 days of vaccination (one in the ALM + BCG group and three in the BCG group), the 2-year incidence of cutaneous leishmaniasis did not differ significantly between vaccine and BCG groups: 2.8% vs 3.3%, respectively (total cases 112). A sex-stratified analysis showed that in boys the vaccine conferred a protective efficacy of 18% and 78% for the first and second years, respectively--a crude 2-year overall protection of 55% (95% CI 19-75%, p < 0.01). In the first 9 months after vaccination, there was a non-significant excess of cases in the ALM + BCG group (25 vs 16), whereas the incidence of cutaneous leishmaniasis thereafter was significantly reduced in the ALM + BCG group (27 vs 44, p < 0.05).

INTERPRETATION

A single dose of ALM + BCG was safe and more immunogenic than BCG alone, as measured by leishmanin skin test. The exact reason for the apparent protective effect of the vaccine in boys is unknown, and may be a chance finding. However, since boys are more exposed to the infection, which is indicated by higher disease prevalence in boys in this study population, the preferential protective effect in boys may have resulted from a greater booster effect produced by repeated exposure to infected sandflies. Booster injections or alternative adjuvants should be tried to improve the potential efficacy of this vaccine.

摘要

背景

在伊朗巴姆进行的一项随机双盲试验中,评估了一种由单剂量全细胞高压灭菌杀死的硕大利什曼原虫(ALM)与卡介苗混合而成的疫苗,与单独使用卡介苗相比,用于预防人源性(人际传播)皮肤利什曼病的效果。

方法

3637名6至15岁、无皮肤利什曼病病史且对利什曼菌素皮肤试验无反应的学童被随机分配接受1毫克ALM与卡介苗混合制剂(n = 1839)或单独的卡介苗(n = 1798)。对疫苗的安全性和确诊皮肤利什曼病病例的发生率进行了2年的随访。

研究结果

副作用是通常与卡介苗接种相关的那些,但在ALM + BCG组中往往持续时间更长。在排除接种疫苗后80天内发生的4例病例(ALM + BCG组1例,卡介苗组3例)后,疫苗组和卡介苗组皮肤利什曼病的2年发病率无显著差异:分别为2.8%和3.3%(总病例112例)。按性别分层分析显示,在男孩中,疫苗在第一年和第二年分别提供了18%和78%的保护效力——粗略的2年总体保护率为55%(95%CI 19 - 75%,p < 0.01)。在接种疫苗后的前9个月,ALM + BCG组的病例数略有增加但无统计学意义(25例对16例),而此后ALM + BCG组皮肤利什曼病的发病率显著降低(27例对44例,p < 0.05)。

解读

单剂量的ALM + BCG是安全的,并且通过利什曼菌素皮肤试验测量,其免疫原性比单独使用卡介苗更强。疫苗对男孩具有明显保护作用的确切原因尚不清楚,可能是偶然发现。然而,由于男孩更容易接触感染,本研究人群中男孩的疾病患病率更高表明了这一点,男孩中的优先保护作用可能是由于反复接触受感染的白蛉产生了更大的增强效应。应尝试进行加强注射或使用替代佐剂来提高这种疫苗的潜在效力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验